1. European Urology Oncology
Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy 
Anis A. Hamid, Kathryn P. Gray, Ying Huang, Michaela Bowden, Mark Pomerantz, Massimo Loda, Christopher J. Sweeney 
European Urology Oncology 
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
PTEN and AMACR (tumor masking) fluorescent immunostaining of tissue microarray cores. (A) Positive (intact) PTEN staining of prostate cancer glands (arrow) that also expressed cytoplasmic AMACR (B, arrow). (C) Absent PTEN in tumor glands (arrows) with positive AMACR (D, arrows) for comparison. (E) Normal prostate tissue with positive PTEN staining of benign glands and stroma. (F) Normal prostate tissue demonstrates a lack of AMACR expression.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier estimates of (A) time to metastasis and (B) overall survival. PTEN expression (nuclear plus cytoplasmic) was analyzed dichotomously, with low indicating expression in the lowest quartile for the cohort and high indicating expression greater than that in the lowest quartile. HR=hazard ratio; CI=confidence interval.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

4. Fig. 3
Comparison of receiver operating characteristic curves for prediction of (A) metastatic disease and (B) death at 10 yr using clinicopathologic factors, PTEN expression (nuclear and cytoplasmic), or a combination of clinicopathologic factors and PTEN expression. AUC=area under the curve.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions